



Original article

Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer

MITSUGU KOCHI, MASASHI FUJII, NORIAKI KANAMORI, TERUO KAIGA, TETSUYA KAWAKAMI, KAZUO AIZAKI, MITSUKO KASAHARA, FUMIRO MOCHIZUKI, YUICHI KASAKURA, and MOTOO YAMAGATA

Third Department of Surgery, Nihon University School of Medicine, 30-1 Ohyaguchi Kamimachi, Itabashi-ku, Tokyo 173-8610, Japan

Abstract

Background. This clinicopathological study evaluated the utility of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 as predictors of locoregional recurrence and long-term disease-free survival in patients with gastric cancer.

Methods. During the period January 1989 to December 1994, 485 patients with primary gastric cancer were evaluated. Gastrectomies were performed in 434 patients. Prognostic factors were analyzed by the Kaplan-Meier method and multivariate analysis, using Cox regression.

Results. Elevated serum CEA and CA19-9 levels were observed in 92 of the 485 patients (19.0%), and in 95 of the 435 patients (21.8%), respectively, and both markers were elevated in 29 of these 435 patients (6.7%). Elevated serum CEA and CA19-9 levels correlated well with lymph node metastasis, lymphatic invasion, vessel invasion, stage grouping, depth of invasion, and curability. Patients with elevated serum CEA levels were at significantly higher risk of having all recurrence factors than were those with normal serum CEA levels. Patients with elevated serum CA19-9 levels were at significantly higher risk of having peritoneal metastases and distant metastases than were those with normal serum CA19-9 levels. A significant difference in the cumulative survival curves of patients was demonstrated between those with elevated and those with normal serum CEA or CA19-9 levels, even for patients at the same disease stage (stage III). Patients with elevated levels of both markers had a significantly worse prognosis than patients in whom the levels of both markers were normal. In patients who underwent gastrectomy, elevated serum CEA levels either preoperatively or within 3 weeks after gastrectomy were associated with significantly worse prognosis than were normal levels. When the cutoff level of serum CEA was increased to 10 ng/ml, serum CEA, age, lymph node metastasis, and surgical stage grouping were

selected as independent prognostic factors by multivariate analysis of 14 prognostic factors, using Cox regression.

Conclusion. Serum CEA and CA19-9 levels provide additional prognostic information in patients with primary gastric cancer. In particular, an elevated serum CEA level provides additional prognostic information and is a useful indicator of curability in patients who undergo gastrectomy. Serum CEA level is an independent prognostic factor in patients with primary gastric cancer.

Key words Tumor marker · CEA · CA19-9 · Gastric cancer · Prognosis

Introduction

In spite of recent improvements in early detection, progress in surgical techniques, and the development of adjuvant chemotherapeutic regimens, the survival of patients with gastric cancer still needs to be improved [1]. Although morbidity and mortality have decreased significantly in the past 40 years, the overall 5-year survival in Japanese patients with gastric cancer remains less than 70% [2]. Distant metastasis, depth of invasion, and lymph node metastasis are well known to be strong prognostic factors [3–6], and, in addition, serum tumor marker levels are considered to be important. Various tumor markers have been described since Gold and Freedman [7] reported the discovery of carcinoembryonic antigen (CEA) in 1965. Serum CEA levels have been studied in an effort to identify those patients who may be at increased risk of recurrence despite curative resection and who are therefore appropriate candidates for adjuvant therapy. In colon cancer, Holyoke et al. [8] reported that when the CEA cutoff value was set at 2.5 ng/dl, there were more recurrences among patients whose preoperative CEA values were above this level. Wanebo et al. [9] reported that when the cutoff value was set at 5 ng/dl, there were significantly more recur-

rences in patients with Dukes B ($P < 0.02$) and Dukes C ($P < 0.001$), suggesting that CEA-positive patients had significantly poorer prognoses.

Another tumor marker, carbohydrate antigen (CA) 19-9 [10], a ligand of E-selectin [11], is a molecule that may play a role in the adhesion of cancer cells to endothelial cells, resulting in hematogenic metastasis. A significant difference has been observed between the prognosis of stage II–III pancreas cancer patients with and without elevated CA19-9 levels [12]. Pronounced expression of CA19-9 has also been observed by immunostaining of gastric cancer tissue [13], making it another of the tumor markers that are frequently evaluated in gastric cancer patients in Japan.

Although serum CEA may be useful in the follow-up of colon cancer to identify tumor recurrence, and CA19-9 may be useful in the follow-up of pancreas cancer, it is, at present, unclear what role tumor markers may have in predicting or identifying those patients with gastric cancer who will develop recurrence after curative resection. Therefore, in this clinicopathological study, we evaluated whether serum CEA and CA19-9 levels predicted locoregional recurrence and long-term disease-free survival in patients with gastric cancer.

Patients and methods

Between January 1989 and December 1994, 485 patients with primary gastric cancer were referred for evaluation. Gastrectomies were performed in 434 patients (resectability rate 89.5%). Of the 434 patients, total gastrectomy was performed in 129 (29.7%), subtotal gastrectomy in 287 (66.1%), and wedge resection in 18 patients (4.1%). All patients had histologically proven adenocarcinoma of the stomach. We selected the following 12 prognostic factors for evaluation: age, sex, main tumor location, tumor size, gross type, clinical stage, histological type, depth of invasion, lymph node metastasis, lymphatic and venous invasion, and curability. For main tumor location, the stomach was divided into upper, middle, and lower positions; histological type was assessed as tub1, tub2, por1, por2, and sig types; depth of invasion (t1, t2, t3, t4), lymphatic and venous invasion, and curability (A, B, C) were classified according to the Japanese classification of gastric cancer (JCGC) [16]. Serum CEA and CA19-9 levels were analyzed in relation to these prognostic factors by multivariate analysis. The preoperative CEA and CA19-9 levels (within 1 month prior to gastrectomy) and the postoperative CEA and CA19-9 levels (within 3 weeks after gastrectomy) were determined in the clinical laboratory. Serum levels of CEA were determined with a commercial enzyme immunoassay kit (Fujirebio; Tokyo, Japan). Serum levels of CA19-9 were also evalu-

ated with a commercial enzyme immunoassay kit (Fujirebio). The cutoff value for CEA was 5 ng/ml and that for CA19-9 was 37 U/ml.

Cumulative survival rates were calculated by the Kaplan-Meier method, and statistical significance was evaluated by the log-rank test. The Survival Tools for StatView program (Abacus Concepts, Berkeley, CA, USA) was used for simultaneous multivariate adjustment of all covariates by Cox regression analysis. Forward stepwise regression analysis (likelihood-ratio statistic) was performed to select good predictors of survival. The relative risk of death was compared by using the exponential coefficient [$\exp(\beta)$]. Statistical significance was assumed for a P value of less than 0.05.

Results

Clinicopathological and surgical features

The patients' clinicopathological and surgical features are shown in Table 1. Their median age was 61.9 years (range, 20–90 years). The ratio of males to females was 3:1. Serum levels of CEA were elevated in 92 of the 485 patients (19.0%), CA19-9 levels were elevated in 95 of the 435 patients (21.8%), and both markers were elevated in 29 of these 435 patients (6.7%). There were no significant differences according to sex between elevated and normal levels for either serum CEA or CA19-9 levels. The proportions of patients with elevated serum CEA and CA19-9 levels were significantly higher in those at stage IV of the JCGC surgical stage grouping than the proportions in patients at other stages (CEA, 53.9%; CA19-9, 51.6%). At stage III and below, the positivity rates for elevated CEA and CA19-9 levels were below 30%. Lymph node metastasis, lymphatic invasion, vessel invasion, stage grouping, depth of invasion, and curability were significantly different between the patients with elevated and those with normal serum levels of either CEA or CA19-9.

The proportions of patients with elevated and those with normal levels of either serum CEA or CA19-9 were compared according to JCGC histological type, but there were no significant differences. However, the proportion of patients with elevated serum CEA levels tended to be higher in those with tub2, and lower in those with tub1 and sig. Elevated serum CA19-9 levels tended to be more frequent in patients with tub2, and lower in those with sig.

Recurrence type

Recurrence type was compared in patients with elevated and those with normal serum levels of either

Table 1. Clinicopathological characteristics

		Serum CEA (n = 485)		<i>P</i>	Serum CA19-9 (n = 435)		<i>P</i>
		Normal	Elevated		Normal	Elevated	
Sex	Male	286 (72.8)	69 (75.0)	NS	253 (74.4)	64 (67.4)	NS
	Female	107 (27.2)	23 (25.0)		87 (25.6)	31 (32.6)	
Age (years)	Median	61.2	61.9	NS	60.9	66.4	NS
	Range	27–90	20–90		20–90	34–90	
Location	Upper	73 (18.9)	22 (25.3)	NS	68 (20.2)	20 (22.2)	NS
	Middle	173 (44.7)	29 (33.3)		143 (42.4)	38 (41.8)	
	Lower	141 (36.4)	36 (41.4)		126 (37.4)	33 (36.3)	
Tumor size (mm)		48.3	56.4	NS	42.7	72.7	NS
Gross type	Ulcerated	256 (67.4)	67 (78.8)	NS	233 (70.6)	54 (61.4)	
	Polypoid	54 (14.2)	2 (2.3)		38 (11.5)	10 (11.4)	
	Diffuse	42 (11.1)	11 (12.9)		36 (10.9)	17 (19.3)	
	Nonclass	28 (7.4)	5 (5.9)		23 (7.0)	7 (8.0)	
Stage	I	176 (46.3)	13 (14.6)	<i>P</i> < 0.001	139 (41.7)	24 (25.3)	<i>P</i> < 0.001
	II	55 (14.2)	12 (13.5)		38 (11.5)	10 (10.5)	
	III	78 (20.5)	16 (18.0)		73 (21.9)	12 (12.6)	
	IV	71 (18.7)	48 (53.9)		65 (19.5)	49 (51.6)	
Histologic type	tub1	54 (14.8)	7 (8.9)	NS	43 (13.6)	10 (12.8)	NS
	tub2	103 (28.3)	31 (39.2)		94 (29.7)	27 (34.6)	
	por1	8 (2.2)	3 (3.8)		8 (2.5)	3 (3.8)	
	por2	161 (44.2)	34 (43.0)		133 (42.1)	35 (44.9)	
	sig	38 (10.4)	4 (5.1)		38 (12.0)	3 (3.8)	
Depth of invasion	t1	165 (47.3)	16 (24.3)	<i>P</i> < 0.005	132 (43.6)	22 (32.4)	<i>P</i> < 0.005
	t2	105 (30.1)	31 (46.9)		111 (36.6)	17 (25.0)	
	t3	74 (21.2)	16 (24.2)		58 (19.1)	26 (38.2)	
	t4	5 (1.4)	3 (4.5)		2 (0.7)	3 (3.8)	
Lymph node meta	n0	215 (63.6)	20 (33.9)	<i>P</i> < 0.0001	181 (61.1)	29 (50.0)	<i>P</i> < 0.005
	n1	70 (20.7)	20 (33.9)		67 (22.6)	12 (20.7)	
	n2	42 (12.4)	10 (16.9)		41 (13.9)	5 (8.6)	
	n3	11 (3.3)	9 (15.3)		7 (2.4)	12 (20.7)	
Lymphatic invasion	ly0	135 (38.8)	12 (18.2)	<i>P</i> < 0.005	113 (37.2)	18 (26.9)	<i>P</i> < 0.0001
	ly1	89 (25.6)	14 (21.2)		78 (25.7)	15 (22.4)	
	ly2	78 (22.4)	23 (34.8)		77 (25.3)	10 (14.9)	
	ly3	46 (13.2)	17 (25.8)		36 (11.8)	24 (35.8)	
Vessel invasion	v0	259 (74.6)	39 (59.1)	<i>P</i> < 0.05	220 (72.6)	44 (65.7)	<i>P</i> < 0.05
	v1	87 (19.3)	20 (30.3)		64 (21.1)	16 (23.9)	
	v2	22 (5.2)	4 (6.1)		17 (5.6)	3 (4.4)	
	v3	6 (0.9)	3 (4.5)		2 (0.7)	4 (6.0)	
Curability	A	184 (46.8)	16 (22.5)	<i>P</i> < 0.0005	155 (50.2)	21 (29.2)	<i>P</i> < 0.0001
	B	126 (32.1)	27 (38.0)		115 (37.2)	23 (31.9)	
	C	83 (21.1)	28 (39.4)		39 (12.6)	28 (38.9)	

Numbers in parentheses are percentages CEA, Carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; NS, not significant

CEA or CA19-9, using four recurrence factors: lymph node metastases, peritoneal metastases, liver metastases, and distant metastases (Table 2). Patients with elevated serum CEA levels were at significantly higher risk of having all recurrence factors than were those with normal serum CEA levels. All factors were analyzed by forward stepwise selection. Liver metastases, distant metastases, and lymph node metastases were selected as independent risk factors, and liver metastasis was the highest risk factor for elevated serum CEA levels. Patients with elevated serum CA19-9 levels were

at significantly higher risk of having peritoneal metastases and distant metastases than were those with normal serum CA19-9 levels. Distant metastases and peritoneal metastases were selected as independent risk factors, and distant metastasis was the highest risk factor for elevated serum CA19-9 levels.

Survival rate

Cumulative survival was compared in patients with primary gastric cancer who had elevated and those who

Table 2. Elevated and normal serum levels of either CEA or CA19-9 according to four recurrence factors

Recurrence factor	Serum CEA			Serum 19-9		
	Normal	Elevated		Normal	Elevated	
H Positive	15 (3.8)	20 (22.0)	$P < 0.0001$	23 (6.8)	7 (7.5)	NS
H Negative	376 (96.2)	71 (78.0)		315 (93.2)	86 (92.5)	
N Positive	131 (33.3)	71 (77.2)	$P < 0.0001$	217 (56.5)	57 (62.0)	NS
N Negative	262 (66.6)	21 (22.8)		167 (43.5)	35 (38.0)	
P Positive	35 (8.9)	18 (19.8)	$P < 0.005$	32 (9.4)	19 (20.4)	$P < 0.005$
P Negative	357 (91.1)	73 (80.2)		310 (90.6)	74 (79.6)	
M Positive	9 (2.3)	10 (11.1)	$P < 0.0001$	7 (2.0)	9 (9.7)	$P < 0.0005$
M Negative	382 (97.7)	80 (88.9)		335 (98.0)	84 (90.3)	

H, Liver metastasis; N, lymph node metastasis; P, peritoneal metastasis; M, distant metastasis




Fig. 1. Comparison of cumulative survival curves according to serum carcinoembryonic antigen (CEA) level and carbohydrate antigen (CA) 19-9 level. Patients with elevated serum CEA or elevated CA 19-9 levels had a significantly worse prognosis than patients with normal levels of either marker ($P < 0.01$)

had normal serum levels of CEA or CA19-9. Patients with elevated serum CEA or CA19-9 levels had a significantly worse prognosis than patients with normal levels of either tumor marker (Fig. 1. $P < 0.01$ for both markers). To evaluate combination assays of serum CEA and CA19-9 levels, cumulative survivorship was compared in four groups (both markers elevated, both normal elevated CEA and normal CA19-9, and elevated CA19-9 and normal CEA) (Fig. 2). Patients in whom serum levels of both CEA and CA19-9 were elevated had significantly worse prognoses than patients in whom the levels of both markers were normal ($P < 0.0001$). No significant difference was demonstrated be-

tween patients with an elevated serum level of CEA and a normal serum level of CA19-9, and those with an elevated serum level of CA19-9 and a normal serum level of CEA.

In this analysis, however, bias may have been introduced by considering the different stages of cancer together. In order to eliminate such bias, cumulative survival rates were compared by surgical stage. Comparison of cumulative survival curves according to the JCGC surgical stage grouping demonstrated that patients at stage III with elevated serum CEA or CA19-9 levels had a significantly worse prognosis than those with normal levels of either tumor marker (Fig. 3; $P <$




Fig. 2. Comparison of cumulative survival curves according to four combinations of serum CEA and CA 19-9 levels. The differences between all groups, except for that between CEA (+)/CA19-9(-) and CEA(-) and CA19-9(+) were significant ($P < 0.001$)





Fig. 3. Comparison of cumulative survival curves in patients classified according to the Japanese classification of gastric cancer (JCGC) surgical stage grouping. Patients at stage III with elevated serum CEA and CA 19-9 levels had a significantly worse prognosis than did patients with normal CEA and CA19-9 levels ($P < 0.01$)

0.01 for both markers). On the other hand for stages I, II, and IV, there were no significant differences between patients in whom the serum level of either CEA or CA19-9 was elevated and that of the either marker was normal. Cumulative survival was also compared in patients with elevated and those with normal serum levels of either CEA or CA19-9 who were classified according to the curative potential of gastrectomy by the JCGC criteria. Patients with elevated serum CEA levels had significantly worse prognoses ($P < 0.05$) than did

patients with normal levels (Fig. 4). However, no significant difference was demonstrated between patients with elevated and those with normal serum CA19-9 levels.

Finally, cumulative survival was studied for patients who showed elevated serum CEA or CA19-9 levels before gastrectomy, in terms of their levels within 3 weeks after gastrectomy. There was a significant difference in survival ($P < 0.01$) between patients whose serum CEA levels remained elevated after gastrectomy




Fig. 4. Cumulative survival was compared in patients with elevated and those with normal serum CEA levels who were classified according to curative potential of gastrectomy by the JCGC criteria. Patients with elevated serum CEA levels had a significantly worse prognosis than did patients with normal CEA levels ($P < 0.05$)




Fig. 5. Comparison of cumulative survival curves of patients with elevated serum CEA levels before gastrectomy according to serum CEA level after resection. A significant difference ($P < 0.01$) was demonstrated between patients whose elevated serum CEA levels became normal after gastrectomy and those whose CEA levels remained elevated

and those whose serum CEA levels became normal (Fig. 5). However, no such significant difference was demonstrated in patients with elevated serum CA19-9 levels.

Comparison of hazard ratios

The 14 prognostic factors and either the CEA or CA19-9 level were analyzed by multivariate analysis, using Cox regression (Table 3). In all analyses, depth of invasion showed the highest [$\exp(\beta)$, value and serum CEA levels showed higher [$\exp(\beta)$] values than serum CA19-9. The serum CA19-9 level was not shown to be a highly significant prognostic factor. Elevation of both markers was not shown to be a significantly high prognostic factor ($P < 0.1$). All factors were analyzed by forward

stepwise selection with Cox regression. When the cutoff level of serum CEA was increased to 10 ng/ml, serum CEA, age, lymph node metastasis, and surgical stage grouping were selected as independent prognostic factors (Table 4).

Discussion

In this clinicopathological study, we evaluated the utility of serum CEA and CA19-9 as predictors of locoregional recurrence and long-term disease-free survival in patients with gastric cancer. Of the 485 patients examined, 73.2% were men and 26.8% were women. The ratio of males to females was 3:1, and there were no significant sex differences between patients with el-

Table 3. Multivariate analysis of prognostic factors by Cox regression

	Category	β	SE	Wald	<i>P</i> value	Exp(β)
CEA(+)	Normal	0				
	Elevated	0.663	0.33	2.012	0.0442	1.941
CA19-9(+)	Elevated	0				
	Normal	0.546	0.397	1.376	0.1689	1.726
CEA(+),CA19-9(+)	Elevated	0				
	Normal	1.023	0.63	1.624	0.1044	2.781
Age (years)		0.25	0.011	2.248	0.0246	1.026
Sex	Female	0				
	Male	0.005	0.277	0.017	0.9862	1.005
Location	Middle				0.1082	
	Lower	0.556	0.293	1.902	0.0572	1.744
	Upper	0.015	0.308	0.05	0.96	1.016
Gross type	Ulcerated				0.1229	
	Polypoid	0.761	0.415	1.835	0.0666	2.141
	Diffuse	0.67	0.36	1.863	0.0624	1.954
	Nonclass	0.377	0.458	0.824	0.4099	1.459
Stage	III				0.2407	
	I	0.089	0.629	0.141	0.8881	1.093
	II	0.273	0.37	0.737	0.4613	1.313
	IV	0.757	0.379	21.996	0.046	2.132
Depth of invasion	t1				0.0019	
	t2	3.178	1.272	2.499	0.0124	24.007
	t3	1.682	0.531	23.166	0.0015	5.375
	t4	0.811	0.486	1.667	0.0955	2.25
Histological type	pol1				0.2513	
	pol2	0.547	0.777	0.704	0.4816	11.728
	tub1	0.795	0.861	0.923	0.356	2.213
	tub2	1.086	0.771	1.408	0.159	2.962
	Sig	0.329	0.97	0.339	0.7348	1.389
Lymph node meta	n0				0.2463	
	n1	0.565	0.34	1.663	0.0963	1.76
	n2	0.466	0.39	1.192	0.2331	1.593
	n3	1.009	0.527	1.914	0.0556	2.743
Lymphatic invasion	ly2				0.0619	
	ly0	0.225	0.517	0.435	0.6639	1.252
	ly1	0.62	0.356	1.745	0.081	1.86
	ly3	0.821	0.319	2.578	0.01	2.274
Venous invasion	v0				0.0003	
	v1	0.062	0.326	0.189	0.8504	1.063
	v2	0.002	0.467	0.004	0.9997	1.002
	v3	2.499	0.612	4.084	<0.0001	12.166
Curability	A				0.2	
	B	0.567	0.405	1.399	0.1617	1.763
	C	1.013	0.567	1.786	0.074	2.754

evated and those with normal serum levels for either CEA or CA19-9. According to a previous report (in Japanese) of the results of treatment for stomach carcinoma in Japan [15], the sex ratio of patients was 66.4% men and 33.6% women, or about 2:1. In our study, the proportion of men was a little higher.

In this study, the proportion of patients with elevated serum CEA levels was 19.0%, similar to findings (10.6% to 50%) in other studies [12,14,17–25], and the corre-

sponding proportion of patients with elevated serum CA19-9 levels was 21.8%, also similar to previous findings (16.0% to 34.6%) [14,22–24]. These rates, however, are thought to depend on tumor progression at the time of detection. When the proportions of patients with elevated serum CEA and CA19-9 levels were assessed in accordance with the comprehensive stage grouping, it was found that the rates increased gradually with stage. At stage III or below, the positivity rates

Table 4. Detection of independent prognostic factors by multivariate analysis with stepwise selection and Cox regression

Category	β	SE	Wald	<i>P</i> value	Exp (β)	95% CI	
CEA(+)	0.749	0.282	2.651	0.008	2.114	1.215–3.677	
Depth	t1			0.0313			
	t2	0.714	0.453	1.576	0.115	2.042	0.840–4.959
	t3	1.216	0.482	2.524	0.0116	3.374	1.312–8.675
	t4	1.517	0.772	1.965	0.0494	4.56	1.004–20.713
n	0			0.1329			
	1	0.663	0.307	2.158	0.0309	1.942	1.063–3.547
	2	0.74	0.347	2.131	0.0331	2.096	1.061–4.138
	3	0.794	0.455	1.746	0.0808	2.211	0.907–5.389
ly	0			0.0217			
	1	0.23	0.436	0.526	0.5987	1.258	0.535–2.959
	2	0.004	0.464	0.008	0.9939	1.004	0.404–2.494
	3	0.778	0.47	1.657	0.0031	2.177	0.867–5.465
ST	0			<0.0001			
	1	0.424	0.44	0.963	0.3354	1.527	0.645–3.617
	2	0.065	0.464	0.139	0.8892	1.067	0.429–2.651
	3	1.297	0.48	2.701	0.0069	3.66	1.427–9.385
Age	0.024	0.009	2.646	0.0109	1.024	1.006–1.044	

CI, Confidence interval; Depth, depth of invasion; n, lymph node metastasis; ly, lymphatic invasion; ST, surgical stage

were less than 30%, but the rates increased significantly, to over 50% for stage IV patients, similar to data reported previously [21].

It is likely that CEA and CA19-9 levels are increased in patients with multiple organ infiltration, advanced lymph node metastasis, peritoneal metastasis, or liver metastasis, or when other distant metastasis occurs. Therefore, we compared recurrence factors in patients with elevated and those with normal serum CEA or CA19-9 levels (Table 2). Patients with elevated serum CEA levels were at significantly higher risk of having all recurrence factors than those with normal serum CEA levels. Liver metastases, distant metastases, and lymph node metastases were selected as independent risk factors, and liver metastasis was the highest risk factor for elevated serum CEA levels. Patients with elevated serum CA19-9 levels were at significantly higher risk of having peritoneal metastases and distant metastases than those with normal serum CA19-9 levels. Distant metastases and peritoneal metastases were selected as independent risk factors, and distant metastasis was the highest risk factor for elevated serum CA19-9 levels.

In patients with gastric cancer, it has been reported that the proportion of those with elevated serum CEA levels increases with advancing cancer stage and liver metastasis [14,17–19,26]. Our study produced similar findings. One study has shown that elevated serum CA19-9 levels in gastric cancer are well correlated with various forms of metastasis [22]. No such correlation was observed in our study. Assessment of average CEA levels by comprehensive clinical stage also shows that CEA levels increase as the disease becomes more ad-

vanced. Thus, we consider that the CEA level is a more useful indicator than the serum CA19-9 level for assessing the stage of gastric cancer and predicting its possible recurrence and metastasis.

We compared other clinicopathological factors in patients with primary gastric cancer who had elevated and those who had normal levels of either serum CEA or CA19-9. The proportions of patients with elevated serum CEA and CA19-9 levels were significantly higher with respect to the factors of stage grouping, depth of invasion, lymph node metastasis, lymphatic invasion, vessel invasion, and curability. Elevated serum CEA or CA19-9 levels were also correlated significantly with these factors. These findings indicate that the proportions patients with elevation of these tumor markers increases as the cancer progresses, similar to the findings of other investigators [18–25].

We also compared cumulative survival in patients with primary gastric cancer who had an elevated serum level of either CEA or CA19-9, with cumulative survival in those with a normal level of either marker. A significant difference was demonstrated between the cumulative survival curves for patients with elevated and those with normal serum CEA or CA19-9 levels (Fig. 1). Similar results in patients with gastric cancer have been reported by others [20–23].

Patients in whom both the serum CEA and CA19-9 levels were elevated had significantly worse prognoses than patients in whom the levels of both markers were normal. No significant difference was demonstrated between patients in whom the serum CEA level was elevated and the serum CA19-9 level was normal, and

patients in whom the serum CA19-9 level was elevated and the serum CEA level was normal (Fig. 2). Similar results in patients with gastric cancer have been reported by others [23].

Comparison of cumulative survival curves according to the JCGC surgical stage grouping showed that, although there were no significant differences between patients with elevated and those with normal serum CEA or CA19-9 levels at stages I, II, and IV, the prognosis for patients at stage III who had elevated serum CEA or CA19-9 levels was worse than that for patients with normal levels (of CEA or CA19-9) ($P < 0.01$) (Fig. 3). Previous studies reported that the survival rate of gastric cancer patients at stages I, II, and III with serum CEA levels below 5 ng/ml was significantly better than that of patients whose serum CEA levels were above this value [20,26]. The survival rate of gastric cancer patients at stage I with serum CA19-9 levels below 37 ng/ml was reported to be significantly better than that of patients with levels above that value [23]. We found no significant differences between patients at stage I, II, and IV who showed elevated serum levels of either CEA or CA19-9 and those with a normal level of either marker, because of the good prognosis after curative gastrectomy at stages I and II, and the worse postoperative prognosis at stage IV.

These findings indicate that serum CEA and CA19-9 levels provide additional prognostic information in patients with primary gastric cancer. We compared cumulative survival in patients with elevated and those with normal serum levels of either CEA or CA19-9 classified for curative potential of gastrectomy according to the JCGC criteria. The gastric cancer patients with serum CEA levels below 5 ng/ml (CEA(-) in Fig. 4) showed significantly better prognosis ($P < 0.05$) (Fig.4). On the other hand, no significant difference could be demonstrated between patients with elevated and those with normal serum CA19-9 levels. These findings indicate that serum CEA levels provide additional prognostic information in patients with gastric cancer who undergo gastrectomy. Similar results in patients with gastric cancer have been reported by others. One study reported that elevated serum CEA levels correlated well with other prognostic information in patients with gastric cancer who underwent curative resection of stage II and III gastric cancer [26]. We also studied cumulative survival studied in those patients who showed elevated serum CEA and CA19-9 levels before gastrectomy, in terms of measurements taken within 3 weeks after tumor resection. Patients whose serum CEA levels became normal after gastrectomy had a significantly better prognosis ($P < 0.01$) than those whose serum CEA levels remained high (Fig. 5). On the other hand, no significant difference could be demonstrated in patients with elevated serum CA19-9 levels.

These results suggest that the level of CEA could be a useful indicator of the curability of gastric resection.

To evaluate the reliability of serum CEA and CA19-9 levels as additional prognostic factors, we performed multivariate analysis with 14 prognostic factors, using Cox regression. In all analyses, venous invasion showed the highest value [$\exp(\beta)$], and serum CEA levels showed higher values [$\exp(\beta)$] than curability, lymphatic invasion, stage grouping, and depth of invasion. Serum CA19-9 levels were not a highly significant prognostic factor. To determine the independent prognostic factors, we then performed forward stepwise selection. When the cutoff level of serum CEA was increased to 10 ng/ml, serum CEA, age, lymph node, metastasis, and surgical stage grouping were selected as independent prognostic factors. Previously, it was reported that preoperative CEA level was a strong prognostic factor [20], although others have reported that only serum CA19-9 level is a good prognostic factor [22]. Elevation of the serum levels of both CEA and CA19-9 was not selected as an independent prognostic factor in our study. A previous study reported that a combination assay of preoperative CEA and CA19-9 levels was an independent prognostic factor. In the present study, the lack of selection of these markers as independent prognostic factors may have been due to the small sample size. However, our data showed that serum CEA level can be an additional independent prognostic factor in patients with primary gastric cancer.

In conclusion, levels of both CEA and CA19-9 provide additional prognostic information in patients with primary gastric cancer. Furthermore, our findings indicate that the preoperative serum CEA level provides additional prognostic information and is a useful indicator of curability in patients with gastric cancer after gastrectomy, as well as being an additional independent prognostic factor in primary gastric cancer.

Acknowledgments We are grateful to Ms. H. Shouno for her assistance with data analysis.

References

1. Fuch CS, Mayer RJ. Gastric carcinoma. *N Engl J Med* 1995; 333:32-41.
2. Masashi F, Juei S, Toshifusa N. State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. *Gastric Cancer* 1999;2:151-7.
3. Maruyama K. The most important prognostic factors for gastric cancer patients. A study using univariate and multivariate analyses. *Scand J Gastroenterol* 1987;22:63-8.
4. Yu CCW, Levison DA, Dunn JA, Ward LC, Demonakou M, Allum WH, et al. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. *Br J Cancer* 1995;71:1106-10.
5. Nakamura K, Ueyama T, Xuan ZX, Ambe K, Adachi Y, et al. Pathology and prognosis of gastric cancer. Findings in 10000

- patients who underwent primary gastrectomy. *Cancer* 1992;70:1030–70.
6. Harrison JD, Fielding JWL. Prognostic factors for gastric cancer influencing clinical practice. *World J Surg* 1995;19:496–500.
 7. Gold P, Freedman SO. Specific carcinoembryonic antigen of the human digestive system. *J Exp Med* 1965;122:467–81.
 8. Holyoke ED, Chu TM, Douglass HO, Evans JT. The role of markers in the management of gastrointestinal cancer. In: Carer SK, Glastein E, Livingston RB, editors. *Principles of cancer treatment*. New York: McGraw-Hill; 1981. pp 456–62.
 9. Wanebo H, Rao B, Pinsky C, Hoffman H. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. *N Engl J Med* 1980;299:448–51.
 10. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. *Somatic Cell Genet* 1979;5:957–72.
 11. Lowe JB, Stoolmann LM, Nair RP, et al. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyltransferase cDNA. *Cell* 1990;63:475–84.
 12. Lundin J, Roberts PJ, Kuusela P, et al. The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. *Br J Cancer* 1994;69:515–9.
 13. Sakamoto J, Watanabe T, Tokumaru T, et al. Expression of Lewis^a, Lewis^b, Lewis^x, sialyl Lewis^a, and sialyl Lewis^x blood group antigens in human gastric carcinoma and normal cancer tissue. *Cancer Res* 1989;49:745–52.
 14. Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of serum and immunohistochemical tumor markers in advanced gastric cancer. *Eur J Cancer* 1996;32A:63–8.
 15. Japanese Gastric Cancer Association (formerly The Japanese Research Society for Gastric Cancer and Miwa Registry — Institute of Stomach Cancer). The registration report and the report of treatment results of stomach carcinoma in Japan 1970–1999 (in Japanese). Vol. 1–55.
 16. Japanese Research Society for Gastric Cancer. *Japanese classification of gastric carcinoma (First English edition)*. Tokyo: Kanehara; 1995.
 17. Janssen CW, Orjasater H. Carcinoembryonic antigen in patients with gastric carcinoma. *Eur J Surg Oncol* 1986;12:19–23.
 18. Shimizu N, Wakatsuki T, Murakami A, Yoshioka H, Hamazoe R, Kanayama H, et al. Carcinoembryonic antigen in gastric cancer patients. *Oncology* 1987;44:240–4.
 19. Koga T, Kano T, Souda K, Oka N, Inokuchi K. The clinical usefulness of preoperative CEA determination in gastric cancer. *Jpn J Surg* 1987;17:342–7.
 20. Nakane Y, Okamura S, Akehira K, Baku T, Okusa T, Tanaka K, Hioki K. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. *Cancer* 1994;73:2703–9.
 21. Maehara Y, Kusumoto T, Takahashi I, Kakeji Y, Baba H, Akazawa K, Sugimachi K. Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with well differentiated gastric cancer. *Oncology* 1994;51:234–7.
 22. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, et al. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. *Am J Gastroenterol* 1996;91:49–53.
 23. Ikeda Y, Oomori H, Koyanagi N, Mori M, Kamakura T, Minagawa S, et al. Prognostic value of combination assays for CEA and CA19-9 in gastric cancer. *Oncology* 1995;52:483–6.
 24. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA19-9 and CA72-4 preoperative serum levels in gastric carcinoma. *Oncology* 1999;57:55–62.
 25. Tachibana M, Takemoto Y, Nakashima Y, Kinugasa S, Kotoh T, Dhar DK, et al. Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. *J Am Coll Surg* 1998;187:64–8.
 26. Ikeda Y, Mori M, Kajiyama K, Kamakura T, Maehara Y, Haraguchi Y, Sugimachi K. Indicative value of carcinoembryonic antigen (CEA) for liver recurrence following curative resection of stage II and III gastric cancer. *Hepatogastroenterology* 1996;43:1281–7.